	[ A1'4' N -	1 A - 1
	Application No.	Applicant(s)
Notice of Allowability	10/773,939	COX, GEORGE N.
	Examiner	Art Unit
	lan Dang	1647
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>01/05/2007</u> .		
2. The allowed claim(s) is/are 25 and 44 (renumbered as claims 1-2).		
<ul> <li>3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have been received.</li> </ul>		
Certified copies of the priority documents have been received in Application No		
Copies of the certified copies of the priority documents have been received in Application 140.  Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
•		
Attachment(s)  1. Notice of References Cited (PTO-892)	5. Notice of Informal I	Patent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6.	/ (PTO-413),
Information Disclosure Statements (PTO/SB/08),     Paper No./Mail Date	7. 🛭 Examiner's Amend	ment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8.  Examiner's Statem	ent of Reasons for Allowance
<b>V</b>	9.  Other	

Application/Control Number: 10/773,939

Art Unit: 1647

**DETAILED ACTION** 

**EXAMINER'S COMMENT** 

After further consideration and Applicants' comment on page 3 of the response mailed

01/05/2007, the Examiner acknowledges that polyethylene glycol is a cysteine-reactive moiety.

Thus the restriction between Group II and subinvention A is hereby withdrawn. Claims 25 and

44 are rejoined.

**EXAMINER'S AMENDMENT** 

An examiner's amendment to the record appears below. Should the changes and/or

additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR

1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the

payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Angela Dallas Sebor on 03/21/2007.

The application has been amended as follows:

In claim 25, line 1, after the term "SEQ ID NO: 17" insert -- of the mature protein thereof--

In claim 25, lines 2-4 deleté "interleukin 11; wherein said variant has biological activity in

vitro as measured by proliferation of a cell line that proliferates in response to interleukin-11"

and insert the following: --SEQ ID NO:17 or the mature protein thereof--.

In claim 44, line 3 after the term "moiety" insert the following --wherein the cysteine-

reactive moiety is polyethylene glycol--.

Page 2

Application/Control Number: 10/773,939

Art Unit: 1647

Delete claim 47.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ian Dang whose telephone number is (571) 272-5014. The examiner can normally be reached on Monday-Friday from 9am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on (571) 272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

lan Dang Patent Examiner Art Unit 1647 March 21, 2007 Budget C. Burner

PATENT EXAMINER

Page 3